FOLH1 and prostate carcinoma: Such an optical contrast exceeded the optical contrast of the fluorescent labels (that were targeted to C4-2B and HS-5 cells using the same prostate cancer-specific PSMA antibody, see Figure 8a an 8e) by 31-times.